Skip to content

Genomic of CONgenital Sideroblastic Anemias

Genomic of CONgenital Sideroblastic Anemias

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07459816
Acronym
GASCON-2
Enrollment
20
Registered
2026-03-10
Start date
2025-10-28
Completion date
2026-11-01
Last updated
2026-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Erythropoiesis, Genetics

Keywords

Anemia, genetics, erythropoiesis

Brief summary

Congenital sideroblastic anemias (CSA) are a group of rare disorders characterized by abnormal iron utilization during erythropoiesis, leading to mitochondrial iron overload, the formation of ring sideroblasts, and ineffective erythropoiesis resulting in anemia. Ring sideroblasts are erythroid precursors that contain non-heme iron deposits in their mitochondria, forming a distinctive ring-like pattern around the nucleus. Mitochondria are double membrane organelle provide a large amount of energy for cellular activities, by the process of oxidative phosphorylation (OXPHOS). The role of mitochondria has been well described in erythropoiesis. CSA exhibits clinical heterogeneity, affecting only the erythroid system in some cases, while in others presenting as part of broader syndromic conditions. Their molecular basis remains imperfectly known, although the development of next- generation sequencing technology brought tremendous advances in the understanding of their genetic features. More than 20 genes have been identified as causative of CSA, with all modes of inheritance observed: X-linked recessive, autosomal dominant, autosomal recessive, pseudo- dominant, and mitochondrial. These genes are typically involved in one of four key mitochondrial pathways: i) Heme biosynthesis (e.g., ALAS2, SLC25A38); ii) Iron-sulfur cluster biosynthesis and transport (e.g., GLRX5, HSPA9, HSCB); iii) tRNA synthesis and maturation (e.g., PUS1, YARS2, LARS2, IARS2, SARS2, MARS1, TRNT1); iv) Mitochondrial respiratory chain synthesis (e.g., NDUFB11). However, in nearly 30% of cases within the French CSA cohort, the underlying genetic cause remains unknown. In these patients with molecularly unexplained whole genome or exome sequencing approaches focusing on genes involved in mitochondrial function and iron metabolism identified several possibly pathogenic variants in CSA patients. These genes were not clearly described as playing a role in erythropoiesis or heme or iron metabolism. We hope to confirm their role in CSA. However, in nearly 30% of cases within the French CSA cohort , the underlying genetic cause remains unknown. The investigators hope to confirm the role in CSA of gene identified with exome sequencing approaches.

Interventions

BIOLOGICALblood redrawal

Peripheral blood mononuclear cells collected in EDTA (7 mL) and ACD tube (7 mL) during a routine sample collection for patients

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patient with unexplained congenital sideroblastic anemia on the molecular side with the gene panels used routinely * Patients already identified by exome sequencing approach carrying bi-allelic variants of candidate genes of the mitochondrial respiratory pathway. * Patients meeting the same criteria who will be identified prospectively over the next 12 months

Exclusion criteria

* NA

Design outcomes

Primary

MeasureTime frameDescription
Identification of genetic variants in Congenital sideroblastic anemias1 yearVariants potentially altering the splicing site
Identification of nonsense and missense genetic variants in Congenital sideroblastic anemias1 yearNonsense and missense variants: study of protein expression or protein size by Western Blot or protein-protein interactions in blood mononuclear cells

Secondary

MeasureTime frameDescription
level of mitochondrial membrane potential1 yearMeasurement of the level of mitochondrial membrane potential (TMRM in flow cytometry)
Measurement of mitochondrial Ros production1 yearMeasurement of mitochondrial Ros production (Mitosox in flow cytometry)
Measurement of mitochondrial mass1 yearMeasurement of mitochondrial mass (MitoTracker in flow cytometry)
Measurement of erythroid differentiation1 yearMeasurement of erythroid differentiation

Countries

France

Contacts

CONTACTOphélie Evrard, MD
evrard.ophelie@chu-amiens.fr33+322835127

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 12, 2026